IVEVF News and Press, Inventiva SA From 12/20/23

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva. With this milestone payment Inventiva expects to have met the operational and financial conditions precedent to draw the second €25...

The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety data The safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for mor...

Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million 2 , and long-term deposit at €5.0 million 3 as of September 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively ...

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker. Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected  ...

2023-09-29 14:58:08 ET Inventiva S.A. (IVA) Q2 2023 Earnings Analyst Conference Call September 29, 2023, 08:00 AM ET Company Participants Frederic Cren - CEO Jean Volatier - CFO Michael Cooreman - Chief Medical Officer Conference Call Participants Ed ...

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million 1 , and long-term deposit at €9.3 million 2 , as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivel R...

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $ 231 million in clinical, regulatory and ...

Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment o...

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million 2 , and long-term deposit at €9.3 million 3 as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively Re...

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million 2 , and long-term deposit at €9.3 million 3 as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively Re...